GO:0000178 exosome (RNase complex): Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000178 describes the exosome (RNase complex), a conserved 3-prime to 5-prime exoribonuclease machine that degrades or processes linear and circular single-stranded RNAs.
• The nuclear exosome is directed to its targets by cofactor complexes such as NEXT and its variant forms, which recognize nascent or aberrant transcripts.
• Structural studies show that the human exosome can form a supercomplex with the ribosome to degrade mRNA, linking RNA decay directly to translation.
• The exosome safeguards genome integrity by resolving R-loops and preventing accumulation of aberrant RNAs, a function required for hematopoietic stem cell self-renewal.
• Dysregulation of exosome components and cofactors is linked to cancer, neurodevelopmental disorders, and innate immune activation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise interrogation of exosome subunit function in cells and animal models.
Description
The exosome (RNase complex), annotated as GO:0000178, is a multi-subunit ribonuclease complex that carries out 3-prime to 5-prime exoribonuclease activity and possibly endoribonuclease activity, producing 5-prime-phosphomonoesters. It is restricted to processing linear and circular single-stranded RNAs, and structured 3-prime ends may require unwinding or pre-processing by cofactors before entry into the complex. This complex participates in a multitude of cellular RNA processing and degradation events that prevent nuclear export and/or translation of aberrant RNAs. Because it controls the fate of many coding and noncoding transcripts, the exosome is central to RNA surveillance, gene expression homeostasis, and genome stability. Researchers study GO:0000178 to understand how cells distinguish normal from aberrant RNAs, how RNA decay is coupled to transcription and translation, and how exosome dysfunction contributes to human disease. The complex is also a target for therapeutic strategies in cancers that depend on high RNA turnover, making its components and cofactors attractive for functional genomics and drug discovery.
exosome (RNase complex) At A Glance
| GO ID | GO:0000178 |
|---|---|
| GO term | exosome (RNase complex) |
| Ontology | cellular_component |
| Synonym | exosome multienzyme ribonuclease complex; exosome (ribonucleasease complex) |
| Major function | 3-prime to 5-prime exoribonuclease activity and possibly endoribonuclease activity on linear and circular single-stranded RNAs, producing 5-prime-phosphomonoesters |
| Substrate specificity | Linear and circular single-stranded RNAs; structured 3-prime ends may require cofactor-mediated unwinding or pre-processing |
| Cofactor complexes | NEXT (nuclear exosome targeting) complex and variant NEXT complexes direct nuclear exosome activity |
| Cellular roles | RNA processing and degradation, prevention of nuclear export and/or translation of aberrant RNAs, R-loop resolution, genome integrity |
| Disease relevance | Cancer, hematopoietic stem cell dysfunction, innate immune activation, neurodevelopmental disorders |
What Is GO:0000178?
GO:0000178, exosome (RNase complex), is a cellular component defined as a ribonuclease complex with 3-prime to 5-prime exoribonuclease activity and possibly endoribonuclease activity, producing 5-prime-phosphomonoesters. It processes and degrades linear and circular single-stranded RNAs, and it prevents nuclear export and/or translation of aberrant RNAs. RNAs with complex secondary structures may need to be unwound or pre-processed by cofactors before they can enter the complex, especially if the 3-prime end is structured. The term is synonymous with exosome multienzyme ribonuclease complex and exosome (ribonucleasease complex).
Why Is exosome (RNase complex) Important in Cell Biology?
The exosome (RNase complex) is essential because it determines the lifetime and quality of nearly every RNA in the cell, from nascent transcripts to stable mRNAs and noncoding RNAs. By degrading aberrant or improperly processed RNAs, it prevents the accumulation of toxic or immunogenic species and preserves genome integrity. Its coupling to the ribosome and to transcription-associated cofactors places it at the interface of RNA synthesis, translation, and decay, making it a key node in gene expression control. Consequently, mutations or dysregulation of exosome subunits and their targeting factors can drive cancer, impair stem cell function, and trigger innate immune responses.
• Maintains RNA quality control by degrading aberrant transcripts that would otherwise be exported or translated.
• Resolves R-loops and protects genomic integrity, a function required for hematopoietic stem cell self-renewal.
• Couples mRNA decay to translation through an exosome-ribosome supercomplex.
• Targets circular RNAs for degradation, expanding its role beyond linear transcripts.
• Is hijacked or dysregulated in cancers, including MYCN- and MYC-driven tumors.
• Supports innate immune homeostasis by preventing accumulation of immunogenic RNA-DNA hybrids.
• Provides a mechanistic basis for understanding neurodevelopmental and ribosomopathy-like phenotypes.
• Offers druggable targets for modulating RNA stability in cancer and immune disorders.
• Serves as a model system for studying cofactor-directed substrate selection.
• Enables functional genomics screens that link RNA decay to cell fitness and differentiation.
What Happens During exosome (RNase complex)?
Substrate Recognition and Targeting
In simple terms: The exosome does not grab every RNA; it waits for helper proteins to bring it the right targets.
The nuclear exosome is directed to its substrates by cofactor complexes such as the nuclear exosome targeting (NEXT) complex, which recognizes nascent or aberrant transcripts and delivers them to the catalytic core. Structural studies of the human NEXT complex reveal how it engages RNA and positions it for degradation, providing a basis for substrate specificity. Variant NEXT complexes can associate with the Microprocessor, indicating that exosome targeting is integrated with other RNA processing machineries. The MYCN oncoprotein can act as an RNA-binding accessory factor of the nuclear exosome targeting complex, linking oncogenic transcription to RNA decay.
Catalytic Degradation of Single-Stranded RNA
In simple terms: Once an RNA is delivered, the exosome chews it from the 3-prime end, releasing small pieces.
The exosome carries out 3-prime to 5-prime exoribonuclease activity, producing 5-prime-phosphomonoesters, and it is restricted to linear and circular single-stranded RNAs. The catalytic subunit DIS3 can degrade circular RNAs, demonstrating that the complex handles topologically diverse substrates. RNAs with structured 3-prime ends may require unwinding or pre-processing by cofactors before entering the complex, ensuring that only accessible ends are degraded.
Coupling to Translation and mRNA Decay
In simple terms: The exosome can work together with ribosomes to break down messenger RNAs while they are being translated.
Structural analysis of the human exosome-ribosome supercomplex shows how mRNA decay is physically and functionally coupled to translation. This coupling allows the cell to coordinate the fate of an mRNA with its translation status, preventing the accumulation of truncated or aberrant polypeptides. The exosome therefore acts as a quality control hub at the interface of translation and RNA turnover.
R-Loop Resolution and Genome Integrity
In simple terms: The exosome helps clean up RNA-DNA hybrids that can otherwise damage DNA.
The nuclear exosome targeting complex safeguards hematopoietic stem cell self-renewal and genomic integrity by resolving R-loops. Loss of this function leads to accumulation of RNA-DNA hybrids and activation of DNA damage responses. MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids, further linking exosome-related RNA handling to immune homeostasis.
Key Genes Involved in GO:0000178 exosome (RNase complex)
The exosome (RNase complex) is built from multiple catalytic and structural subunits, and its activity is controlled by accessory factors and cofactor complexes that together determine substrate specificity and cellular outcomes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DIS3 | Catalytic 3-prime to 5-prime exoribonuclease subunit; degrades linear and circular RNAs | Target for RNA stability studies and cancer models |
| EXOSC1 | Core structural subunit of the exosome complex | Knockout models to study complex assembly and RNA processing |
| EXOSC2 | Core subunit implicated in RNA surveillance | Linked to neurodevelopmental and ribosomopathy-like phenotypes |
| EXOSC3 | Core subunit required for exosome integrity | Disease models for pontocerebellar hypoplasia and RNA processing defects |
| EXOSC4 | Core subunit contributing to catalytic architecture | Functional studies of exosome assembly and substrate channeling |
| EXOSC5 | Core subunit involved in RNA binding | CRISPR knockout to assess RNA decay and cell fitness |
| EXOSC6 | Core subunit stabilizing the complex | Structural and biochemical studies of exosome composition |
| EXOSC7 | Core subunit with RNA-binding surfaces | Mutational analysis of substrate recognition |
| EXOSC8 | Core subunit required for nuclear exosome function | Models of RNA processing disorders |
| EXOSC9 | Core subunit linked to RNA surveillance | Knockout and knock-in studies of exosome-related disease |
| EXOSC10 | Nuclear exosome-associated factor with exonuclease activity | Studies of nuclear RNA turnover and R-loop biology |
| ZCCHC8 | NEXT complex component that recognizes RNA substrates | Structural and functional studies of targeting |
| RBM7 | NEXT complex RNA-binding subunit | Knockout models to define substrate specificity |
| MTREX (SKIV2L2) | RNA helicase in NEXT complex that unwinds structured RNA | Studies of cofactor-dependent exosome activation |
| MYCN | RNA-binding accessory factor of the nuclear exosome targeting complex | Cancer models linking oncogenic transcription to RNA decay |
| MYC | Transcription factor that binds nascent RNA and influences R-loop-derived hybrids | Models of innate immune signaling and genome stability |
| DIS3L | Cytoplasmic exosome-associated exonuclease | Comparative studies of nuclear versus cytoplasmic decay |
How Is exosome (RNase complex) Regulated?
Exosome (RNase complex) activity is regulated at multiple levels, including cofactor availability, substrate recognition, and coupling to transcription and translation. The NEXT complex and its variant forms determine which nuclear transcripts are delivered to the catalytic core, and structural studies show how these cofactors engage RNA. The MYCN oncoprotein can act as an RNA-binding accessory factor of the nuclear exosome targeting complex, linking oncogenic transcription to RNA decay. MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids, indicating that transcription factors can modulate the RNA substrates that feed into exosome-related pathways. The exosome-ribosome supercomplex provides a physical link between translation and mRNA decay, allowing the cell to coordinate these processes. In hematopoietic stem cells, the nuclear exosome targeting complex is required to resolve R-loops and maintain genomic integrity, suggesting that cell-state-specific factors regulate its activity.
exosome (RNase complex) and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYCN | Oncogenic RNA decay and neuroblastoma biology | MYCN overexpression and knockout cell models |
| MYC | R-loop-derived RNA-DNA hybrids and innate immune signaling | MYC-inducible systems with RNA-seq and R-loop mapping |
| EXOSC3 | Neurodevelopmental and ribosomopathy-like phenotypes | CRISPR knock-in of patient variants in neuronal cells |
| EXOSC8 | RNA processing disorders | Knockout and rescue models in stem cells |
| DIS3 | Cancer-associated RNA turnover | Point-mutation and knockout models in myeloma and solid tumor lines |
Cancer and Oncogenic RNA Decay
The exosome (RNase complex) is increasingly recognized as a vulnerability in cancers driven by high transcriptional output, including MYCN- and MYC-driven tumors. MYCN functions as an RNA-binding accessory factor of the nuclear exosome targeting complex, linking oncogenic transcription to RNA decay and suggesting that exosome targeting can be co-opted to support tumor cell fitness. MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids, and disruption of this axis can trigger immune activation. These findings position exosome components and cofactors as potential therapeutic targets in oncology.
Hematopoietic Stem Cell Dysfunction and Genome Instability
The nuclear exosome targeting complex safeguards hematopoietic stem cell self-renewal and genomic integrity through resolving R loops. Loss of this function leads to R-loop accumulation, DNA damage, and impaired stem cell maintenance, highlighting the exosome as a guardian of genome stability in regenerative tissues. This has implications for bone marrow failure syndromes and for understanding how RNA processing defects contribute to stem cell exhaustion.
Neurodevelopmental and Ribosomopathy-Like Disorders
Core exosome subunits such as EXOSC2, EXOSC3, and EXOSC8 have been linked to neurodevelopmental and ribosomopathy-like phenotypes, although the precise mechanisms remain under investigation. Because the exosome processes many noncoding and coding RNAs, its dysfunction can broadly impact gene expression in the nervous system. Model systems using CRISPR knockout and knock-in are valuable for dissecting these disease mechanisms.
Innate Immune Activation and RNA Sensing
Accumulation of aberrant RNAs and R-loop-derived RNA-DNA hybrids can activate innate immune signaling when exosome-related surveillance is compromised. MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids, illustrating how RNA handling pathways intersect with immune sensing. This connection suggests that modulating exosome activity could influence inflammatory and autoimmune phenotypes.
From exosome (RNase complex)-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a core exosome subunit impair RNA surveillance? | CRISPR knockout of EXOSC genes followed by RNA-seq |
| How do point mutations in DIS3 affect circular RNA degradation? | Point-mutation knock-in of DIS3 catalytic residues |
| Can a tagged exosome subunit reveal interaction partners? | Knock-in of epitope-tagged EXOSC or DIS3 for proteomics |
| Does overexpression of MYCN alter exosome targeting? | MYCN overexpression with NEXT complex immunoprecipitation |
| How does exosome dysfunction affect R-loop accumulation? | Knockout of nuclear exosome targeting components with R-loop mapping |
| Can exosome activity be modulated pharmacologically? | Overexpression and knockout models treated with RNA decay inhibitors |
How to Study the exosome (RNase complex) Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Steady-state RNA levels and processing intermediates | Identifying transcripts that accumulate upon exosome loss |
| Degradome sequencing | RNA decay intermediates and 3-prime ends | Mapping exosome cleavage sites |
| Cryo-EM | Three-dimensional structure of exosome complexes | Understanding substrate channeling and cofactor binding |
| Affinity proteomics | Protein-protein interactions of exosome subunits | Discovering cofactors such as NEXT components |
| DRIP-seq / R-loop mapping | RNA-DNA hybrid accumulation | Assessing genome integrity upon exosome dysfunction |
| CRISPR knockout screens | Gene requirements for cell fitness | Identifying exosome vulnerabilities in cancer |
| Immunofluorescence | Subcellular localization of exosome subunits | Validating nuclear versus cytoplasmic pools |
| Circular RNA assays | Levels of circular RNAs | Testing DIS3-dependent degradation |
RNA Sequencing and Degradome Analysis
RNA-seq and specialized degradome approaches can quantify changes in RNA stability and processing upon exosome perturbation. These methods reveal which transcripts accumulate when core subunits or cofactors are lost, providing a global view of exosome substrates. Circular RNA-specific workflows are needed to capture DIS3-dependent degradation of circular species.
Structural Biology and Proteomics
Cryo-electron microscopy and crystallography have resolved the architecture of the human exosome and its complexes with cofactors and the ribosome. Affinity purification coupled to mass spectrometry identifies interaction partners such as NEXT components and accessory factors. These approaches define how substrate channeling and cofactor binding control catalysis.
R-Loop Mapping and Genome Integrity Assays
R-loop mapping methods such as DRIP-seq and related techniques can detect RNA-DNA hybrids that accumulate when exosome targeting is compromised. DNA damage markers and comet assays complement these approaches to assess genome integrity. These methods are particularly relevant in hematopoietic stem cells and cancer models.
CRISPR Screens and Functional Genomics
Pooled CRISPR knockout screens can identify exosome subunits and cofactors required for cell fitness, differentiation, or drug resistance. Focused screens targeting RNA decay factors can uncover synthetic lethal interactions in cancer cells. These functional genomics approaches link exosome biology to specific cellular phenotypes.
How CRISPR Can Be Used to Study GO:0000178 exosome (RNase complex)
Knockout
CRISPR knockout of core exosome subunits such as EXOSC3, EXOSC8, or DIS3 can reveal essential functions in RNA surveillance and cell viability. Knockout models are used to identify transcripts that depend on the exosome for degradation and to assess R-loop accumulation. These models also help define which cofactors are required for specific substrates.
Point Mutation
Point-mutation knock-in of catalytic residues in DIS3 or other subunits allows separation of catalytic activity from structural roles. Such models are valuable for testing whether exonuclease activity is required for circular RNA degradation and for specific disease phenotypes. They also enable structure-function studies guided by cryo-EM data.
Knock-in
Knock-in of epitope tags or fluorescent reporters into endogenous exosome subunit loci enables real-time tracking and interaction proteomics. Tagged knock-in models preserve endogenous regulation and are useful for studying assembly and localization. Disease-associated variants can also be knocked in to model patient-specific effects.
Overexpression
Overexpression of exosome subunits or cofactors such as MYCN can test gain-of-function effects on RNA decay and innate immune signaling. These models are particularly useful in cancer research where oncogenic transcription factors modulate RNA handling. Overexpression combined with RNA-seq and R-loop mapping can reveal dose-dependent effects on genome stability.
How EDITGENE Supports exosome (RNase complex) Research
Researchers studying exosome (RNase complex)-related genes often need to determine whether a candidate gene is causally involved in RNA surveillance, genome stability, or disease phenotypes, and CRISPR-based models provide a direct way to test these hypotheses. Whether the goal is to eliminate a subunit, introduce a patient variant, tag an endogenous protein, or overexpress an oncogenic cofactor, the right model system is critical for reproducible and publication-ready results.
Contact EDITGENE today to design your custom CRISPR model for exosome (RNase complex) research.
Frequently Asked Questions About exosome (RNase complex)
What is GO:0000178 exosome (RNase complex)?
GO:0000178 describes a ribonuclease complex with 3-prime to 5-prime exoribonuclease activity and possibly endoribonuclease activity, producing 5-prime-phosphomonoesters, that processes and degrades linear and circular single-stranded RNAs.
What genes are involved in the exosome (RNase complex)?
Core subunits include DIS3 and EXOSC1-EXOSC10, while cofactors such as ZCCHC8, RBM7, and MTREX form the NEXT complex that targets substrates.
What does the exosome (RNase complex) do in cells?
It degrades or processes aberrant and normal RNAs, prevents nuclear export and translation of aberrant transcripts, resolves R-loops, and couples mRNA decay to translation.
How is the exosome (RNase complex) targeted to its substrates?
Cofactor complexes such as NEXT and variant NEXT complexes recognize nascent or aberrant RNAs and deliver them to the catalytic core.
Can the exosome (RNase complex) degrade circular RNA?
Yes, the catalytic subunit DIS3 can degrade circular RNAs, expanding the substrate repertoire beyond linear transcripts.
What diseases are linked to exosome (RNase complex) dysfunction?
Dysfunction has been linked to cancer, hematopoietic stem cell failure, innate immune activation, and neurodevelopmental or ribosomopathy-like phenotypes.
How do researchers study the exosome (RNase complex)?
Common methods include RNA-seq, degradome sequencing, cryo-EM, affinity proteomics, R-loop mapping, and CRISPR screens.
What is the NEXT complex and how does it relate to the exosome?
The nuclear exosome targeting (NEXT) complex is a cofactor that binds RNA and delivers it to the nuclear exosome for degradation.
Is the exosome (RNase complex) involved in cancer?
Yes, exosome components and cofactors are implicated in MYCN- and MYC-driven cancers and represent potential therapeutic targets.
How can CRISPR help study exosome (RNase complex) genes?
CRISPR knockout, point-mutation, knock-in, and overexpression models allow precise tests of exosome subunit function in RNA decay, genome stability, and disease.
Conclusion
The exosome (RNase complex), GO:0000178, is a central RNA decay machine that shapes transcriptomes, protects genome integrity, and interfaces with translation and innate immunity. Its dysfunction is linked to cancer, stem cell failure, and neurodevelopmental phenotypes, making it a high-value target for functional genomics and therapeutic research. CRISPR-based models, combined with RNA-seq, proteomics, and structural approaches, provide the tools needed to dissect its mechanisms and disease relevance.
References
- 1. Papadopoulos D et al.. 2024. The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex.. Mol Cell 84(11):2070-2086.e20 PMID: 38703770
- 2. Tao X et al.. 2025. Degradation of circular RNA by the ribonuclease DIS3.. Mol Cell 85(8):1674-1685.e8 PMID: 39965568
- 3. Uhl L et al.. 2026. MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids.. Cell 189(5):1371-1388.e29 PMID: 41576951
- 4. Puno MR et al.. 2022. Structural basis for RNA surveillance by the human nuclear exosome targeting (NEXT) complex.. Cell 185(12):2132-2147.e26 PMID: 35688134
- 5. Pan Y et al.. 2025. Nuclear exosome targeting complex safeguards hematopoietic stem cell self-renewal and genomic integrity through resolving R loops.. Cell Rep 44(12):116650 PMID: 41353749
- 6. Kögel A et al.. 2024. Structural basis of mRNA decay by the human exosome-ribosome supercomplex.. Nature 635(8037):237-242 PMID: 39385025
- 7. Kilchert C. 2020. RNA Exosomes and Their Cofactors.. Methods Mol Biol 2062:215-235 PMID: 31768979
- 8. Imamura K et al.. 2024. A functional connection between the Microprocessor and a variant NEXT complex.. Mol Cell 84(21):4158-4174.e6 PMID: 39515294
